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Introduction
Despite the effective frontline treatment of classical Hodgkin 
lymphoma (cHL), about 10% of early-stage and 30% of advanced 
stage patients experience disease relapse or have refractory disease 
[1]. Only half of relapsed/refractory (R/R) patients can be cured with 
salvage chemotherapy followed by high-dose chemotherapy (HDT) 
and autologous stem cell transplantation (ASCT) [2]. For patients 
relapsing after second-line treatment, the possible effective therapy 
option can be salvage treatment with novel agents that have emerged 
in recent years. Histopathologically cHL is characterized by minority of 
malignant cells represented by clonal malignant Hodgkin and Reed-
Sternberg (HRS) cells and the domination of inflammatory and immune 
cells [3, 4]. The HRS cells present the expression of CD30 antigen and 
produce molecules inhibiting T-cell-mediated immune response [5]. 
HRS cells achieve immune evasion by multiple mechanisms including 
enhanced expression of programmed cell death-1 ligands (PD-L1 
and PD-L2) that bind programmed cell death protein 1 (PD-1) on the 
surface of antigen-experienced T cells to suppress T-cell activation 
[6]. Considering the molecular mechanism of action in cHL, in multiply 
relapsed settings the major targets are CD30 expressed by HRS cells 
and PD-1, PD-L1 and PD-L2 which are overexpressed in HRS cells 
due to chromosome 9p24.1 amplification [5]. The breakthrough in 
the therapy of R/R cHL was the development of brentuximab vedotin 
(BV), an antibody-drug conjugate (ADC) targeting the CD30 antigen 
and demonstrating activity as salvage regimen, after ASCT and even 
after allogeneic stem cell transplantation (allo-SCT) failure [7-10]. 
Nivolumab is an IgG4 fully human anti-PD-1 monoclonal antibody 
(mAb) with proven efficacy in a number of solid tumors. Its activity 
was first demonstrated in R/R cHL in a phase I CheckMate 039 study 
[11] and further supported by the results of phase II, CheckMate 
205 study conducted in BV-naïve and relapsed after BV-ASCT 
combination [12]. The results of these studies led to the approval 
of nivolumab in monotherapy by the Food and Drug Administration 
(FDA) [13] and by the European Medicines Agency (EMA) [14] for 
R/R cHL patients who failed ASCT and BV or who are transplant-
ineligible and have failed BV.
The objective of this retrospective analysis was to evaluate the 
efficacy and safety of nivolumab in R/R cHL patients after BV failure 
(real-life experience).
Material and methods
In this retrospective analysis, we collected the data of 16 R/R cHL 
adult patients treated with single-agent nivolumab as salvage regimen 
in 5 Polish Lymphoma Research Group (PLRG) centers. Nivolumab 
was administered after failure of BV treatment. The diagnosis 
according to the World Health Organization 2008 classification, was 
based on histopathological assessment of tissue samples excised 
before the first-line therapy [15]. At baseline staging according to 
Ann Arbor classification, Eastern Cooperative Oncology Group 
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performance status (ECOG PS) and International Prognostic Index 
(IPI) were assessed.
Patients received nivolumab intravenously over 60 minutes at 3 mg/ 
kg every 2 weeks until disease progression or unacceptable toxicity. 
Efficacy data including overall response rate (ORR), complete 
remission (CR) rate, progression-free survival (PFS) and overall 
survival (OS) as well as the safety data were collected. Computed 
tomography (CT) scans of neck, chest, abdomen and pelvis were 
obtained before therapy, 3 months after starting treatment and 
repeated every 6 months. 18F-fluorocholine deoxyglucose positron 
emission tomography (PET) combined with computed tomography 
(PET-CT) was performed before nivolumab treatment and for 
confirmation of suspected progressive disease (PD). Response 
evaluation was performed according to 2014 Lugano classification 
[16]. Eligible patients with objective response to treatment were 
considered for consolidation with either HDT/ASCT or allo-SCT 
according to the local policy. For patients who discontinued nivolumab 
to proceed to transplantation, disease assessment (CR, non-CR) was 
performed according to local standards and clinical symptoms. The 
data on the transplantation and graft-versus-host-disease (GVHD) 
were collected. HDT platinum-based and ifosfamide-containing 
regimens [17-22] and myeloablative conditioning were administered 
according to standard criteria [23]. Supportive treatment was 
administered as required according to the local standards, including 
adequate fluid intake and allopurinol for tumor lysis syndrome 
prevention. Safety outcomes were the incidence of adverse events 
(AEs), classified according to the National Cancer Institute Common 
Terminology Criteria for Adverse Events (CTCAE), version 4.03 [24].
To characterize the study group and response to therapy we used 
descriptive statistical methods. Survival analysis was performed by 
Kaplan-Meier method; both PFS and OS were calculated from the 
time Nivolumab therapy was initiated to time of progression, death 
from any cause or the date of the last follow-up. Statistical analyses 
were performed using the software Statistica, version 10 (StatSoft, 
Krakow, Poland).
Results
Between September 2016 and November 2018, a total of 16 adult 
patients with R/R cHL received single-agent nivolumab at 5 Polish 
sites. Overall, 38% (6/16) of the patients were men, 50% (8/16) had 
stage IV disease, 44% (7/16) presented extranodal involvement at 
diagnosis and 81% (13/16) had B symptoms as weight loss, night 
sweats or fever. The median age at the start of treatment was 30 years 
(range 18-51), median IPI score was 4 (range 2-6). The following 
histopathological subtypes were diagnosed: nodular sclerosis (NS), 
mixed cellularity (MC) and lymphocyte depleted (LD) in 88% (14/16), 
12% (1/16) and 12% (1/16) of patients, respectively. The patients 
did not present any other immune diseases at the start of nivolumab 
treatment. Patient characteristics and demographics are presented 
in table I.
As frontline regimen 75% (12/16) of patients were treated with 6 cycles 
of ABVD (adriamycin, bleomycin, vinblastine and dacarbazine), 25% 
(4/16) with 2 cycles of dose-escalated BEACOPP (escBEACOPP) 
(bleomycin, etoposide, adriamycin, cyclophoshamide, vincristine, 
procarbazine and prednisone) followed by 4 cycles of ABVD. 
6 patients (37%) had primary refractory disease not responding to 
standard regimen and BV. All patients failed BV after the median 
number of cycles equal to 7 (range 2-16), with 56% (9/16) refractory 
to BV. The median number of prior to BV lines of therapy was 
2 (range 2-3). The median age at the start of BV treatment was 
28 years (range 18-50). Because the entire group was treated 
with both BV and nivolumab, the distribution of histopathological 
subtypes of cHL concerns both groups. Prior to BV 31% (5/16) of 
patients relapsed after ASCT. Median time between the last dose of 
brentuximab vedotin and the first dose of nivolumab was 7 months 
(range 1-47). Prior to nivolumab 44% (7/16) of patients relapsed 
after ASCT. The median number of prior lines was 3 (range 2-6). 
Radiotherapy was carried out in 56% (9/16) of patients. The median 
number of nivolumab cycles was 29 (range 3-34). There were no 
dose reductions or dosing interruptions. After six cycles of nivolumab 
ORR was 81% (13/16) with a CR rate of 56% (9/16) and partial 
remission (PR) rate of 25% (4/16). Three patients (19%) had a 
stable disease (SD) and progressed after 12 cycles of nivolumab. 
One of responding patients (8%), having achieved PR experienced 
progressive disease after 19 cycles of nivolumab. Among patients, 
who were refractory to BV, nivolumab treatment resulted with ORR 
in 67% (6/9). The main reason for discontinuation was progressive 
Table I. Baseline patient and disease characteristics
Patient Demographics
Male, n (%) 6 (38)
Female, n (%) 10 (62)
Median age, years (range) 30 (18-51)
Median number of prior treatments, n (range) 3 (2-6)
Histologic subtype n (%)
NS 14 (86)
MC 1 (12)
LD 1 (12)
ECOG PS n (%)
0-1 12 (75)
≥ 2 4 (25)
Stage, n (%)
I 0 (0)
II 7 (44)
III 1 (6)
IV 8 (50)
B symptoms, n (%) 13 (81)
Bulky disease, n (%) 11 (69)
Extranodal involvement, n (%) 44 (7)
Median IPI, number (range) 4 (2-6)
Disease status
Primary refractory, n (%) 6 (37)
Relapsed, n (%) 10 (62)
ASCT before nivolumab, n (%) 44 (7)
ASCT – autologous stem cell transplantation, ECOG PS – Eastern Cooperative 
Oncology Group Performance Status, IPI – International Prognostic Index, LD – 
lymphocyte depleted, MC – mixed cellularity, NS – nodular sclerosis
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disease (25%, 4/16) and allo-SCT (50%, 8/16). The median PFS was 
not reached after a median follow-up of 19 months, estimated PFS at 
20 months was 72% (Fig. 1), with a statistically significant difference 
compared to BV treatment (p < 0.05) (Fig. 2). During observation 3 
patients died; one from disease progression, next two patients due to 
complications after allo-SCT. All deaths were not related to nivolumab 
therapy. During nivolumab treatment, adverse events of any grade 
occurred in 12 patients (75%), including grade-3 AEs observed in 
5 patients (31%) (Tab. II). The most common drug-related AEs of 
any grade were fatigue, rash and diarrhea. Infusion-related reactions 
(IRR) grade 2 were observed in 3 patients (19%) and did not cause 
treatment interruption. There were no AEs of grade 4 or 5. The details 
of AEs are summarized in table II.
In total, 8 patients (62% of responding patients) stopped nivolumab 
treatment and proceeded to allo-SCT after a median of 25 nivolumab 
doses (6 patients from sibling donors, 2 from matched unrelated 
donors). Responses at the time of transplantation were only complete 
remission. Most patients (75%, 6/8) received nonmyeloablative 
conditioning. Median time from the last dose of nivolumab to allo-
SCT was 20 days. Median follow-up after allo-SCT was 6 months. 
Acute graft versus host disease (aGVHD) was not reported. 
Cutaneous chronic graft versus host disease (cGVHD) was noted 
in 2 patients. After allo-SCT 2 patients died; the first one because of 
thrombotic thrombocytopenic purpura (TTP), the second one due to 
massive mycosis and fungal pneumonia. We did not observe disease 
progressions after allo-SCT.
Discussion
Outcomes for patients with cHL have improved significantly over the 
last decades thanks to the effective frontline chemotherapy such 
as ABVD or escBEACOPP [25]. However, R/R cases, both in the 
pretransplant setting and relapsing after ASCT, have a high priority 
to the use of novel agents, not only short-term effective, but also 
overcoming disease resistance. In the pivotal phase II study, BV has 
shown significant clinical efficacy in R/R cHL patients after ASCT 
with ORR of a75%, CR of 34% and a median PFS of 9.3 months 
[7, 26]. Patients who are refractory or relapse after BV therapy 
are a challenge. PD-1 blocking antibodies now represent a major 
breakthrough in the treatment of R/R cHL after ASCT and BV. After 
the encouraging data from extended analysis of three CheckMate 
205 cohorts [27], confirming the efficacy and favorable safety profile 
Table II. Adverse events, according to CTCAE ver 4.03
Adverse event All grade n (%) Grade 1, n (%) Grade 2, n (%) Grade 3, n (%) Grade 4, n (%)
ADVERSE EVENTS
Fatigue 4 (25) 1 (6) 1 (6) 2 (12) 0
Rash 2 (12) 0 1 (6) 1(6) 0
Diarrhea 2 (12) 0 1 (6) 1 (6) 0
Neutropenia 1 (6) 0 0 1 (6) 0
Pneumonia 1 (6) 0 1 (6) 0 0
Pyrexia 1 (6) 1 (6) 0 0 0
Lipase increased 1 (6) 0 1 (6) 0 0
INFUSION-RELATED REACTIONS
Infusion-related reactions 3 (19) 0 3 (19) 0 0
Fig. 1. Progression-free survival in the analyzed group Fig. 2. Comparison of progression-free survival after brentux- 
imab vedotin and nivolumab treatment
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of nivolumab in R/R cHL patients, the efficacy of PD-1 blockade in 
R/R cHL was supported by the phase II study with pembrolizumab 
[28] .
Our real-life experience with nivolumab in R/R cHL patients who 
failed after BV therapy, showed a higher response rate (81%) and 
CR rate (56%) comparing to similar population of patients from cohort 
C of Checkmate205 study (patients after BV and/or ASCT, with 69% 
ORR and 12% CR) [27]. CR rates were assessed by CT scans, we 
did not perform PET assessment to confirm CR, because the immune 
reactions within tumours that may have contributed to persistence 
of fluorodeoxyglucose (FDG) uptake and thereby understate the CR 
rate [12]. We understand that in real-life the confirmation of CR was 
carried out by investigators, not the independent reviewers, however 
the results are encouraging, though needing further observation and 
evaluation. Furthermore, it is worth noting, that the high percentage 
of responders was obtained in patients refractory to BV (67%). It may 
be related to the mechanism of PD-1 blockade, completely different 
from the mechanism of cytostatics and ADC such as BV.
The role of allo-SCT consolidation after anti-PD-1 treatment is still 
unclear because of the higher risk of GVHD [11, 12]. On the other 
hand, there are limited therapeutic options available in the case of 
disease relapse. At this time it is difficult to make any conclusions 
regarding the use of nivolumab as a bridge to allo-SCT, but certainly 
transplantation continues to be a therapeutic option for these patients 
[12, 27]. In a phase 1 study four of five patients died following 
complications after allo-SCT [12]. In Polish experience the results 
are much better. Eight patients proceeded to transplantation, two of 
them (25%) died due to complications related to allo-SCT, but six 
are still alive (75%), with no chance for survival in the pre-nivolumab 
era. Nivolumab demonstrated an accaptable safety profile in clinical 
trials and in real-life. We did not qualify to nivolumab therapy 
patients with a diagnosis of active autoimmune diseases, receiving 
systemic full dose corticosteroids or immunosuppressive therapy 
due to the higher risk of autoimmune toxicities. In the analysis of 52 
advanced melanoma patients with preexisting autoimmune disorders, 
treatment with nivolumab induces 30% autoimmune diseases with 
the majority of rheumatoid disorders [29]. Interestingly, the use of 
immunosupressive drugs resulted in lower response rates [29]. 
The AEs rate in our analysis was favorable; reported events were 
menegable and acceptable. AEs were mainly grade 1-2, grade 3 AEs 
occured in 31% of patients and resolved after supporting treatment. 
Grade 4-5 AEs were not reported.
The study has limitations, due to its retrospective character, limited 
number of patients and short follow-up period. Further evaluation of 
optimal length of treatment, possibility to continue treatment beyond 
progression until clinical benefit is maintained is needed.
In conclusion, the data from this retrospective analysis confirm 
the high efficacy and safety of nivolumab monotherapy in heavily 
pretreated R/R cHL patients in routine clinical practice. Nivolumab 
– a novel drug potentially transforming the treatment landscape in 
HL, may provide long-term benefits to a group of patients deprived 
of other effective options. Sustained benefits were seen across 
different populations including primary refractory patients, relapsed 
after ASCT or refractory to BV. Presented by us analysis lend further 
support confirming the hypothesis of durable benefit from PD-1 
blockage, even in primary refractory patients. The long-term follow-up 
is required to provide additional information on the real-life efficacy, 
safety and outcomes of post-allo-SCT patients after PD-1 blockade.
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